Letter to Shareholders Oct. 10

1 Letter to shareholders l Oct. 2010 l LETTER TO SHAREHOLDERS ISSUE 01 - October 2010 Dear Shareholders, Biology is at a major turning point. For the past 30 years, scientists worldwide have devoted their energies to the discovery of new genes. We are now... More

1 Letter to shareholders l Oct. 2010 l LETTER TO SHAREHOLDERS ISSUE 01 - October 2010 Dear Shareholders, Biology is at a major turning point. For the past 30 years, scientists worldwide have devoted their energies to the discovery of new genes. We are now entering the post-genomic era. The major tasks facing us have moved from deciphering the entire human genome to understanding how genes function and how to maximize their potential in industrial applications, such as manufacturing, therapeutics and agricultural biotechnology. As a pioneer in our domain, Cellectis brings passion, innovation and expertise to the field of genome engineering and is developing products that are going to revolutionize Life Sciences through the entire value chain, from fundamental research to molecular medicine. We have made solid progress during the first half of 2010 in our key business sectors. In therapeutics, we have achieved important milestones, namely in the Duchenne muscular dystrophy field and in i Less